15 completed, 3 active not recruiting, 3 terminated, 2 unknown. 25 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 15, Active not recruiting 3, Terminated 3, Unknown 2, Withdrawn 2 |
| Phase 1 | 8 | Completed 4, Unknown 2, Active not recruiting 1, Withdrawn 1 |
Follow Ixazomib Citrate: new trials by email Literature Review of Ixazomib Citrate trials Research Report on Ixazomib Citrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Ixazomib for Kaposi Sarcoma Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire Administration - Kaposi Sarcoma, Skin | Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 41 | 2023-11-07 | 2026-11-02 |
| A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Ixazomib, Thalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Withdrawn | Takeda | 2019-09-30 | 2020-01-14 | |
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Ixazomib, Ixazomib Citrate, Rituximab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2019-08-28 | 2025-04-20 |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Dexamethasone, Ixazomib, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-06-21 | 2019-03-26 | |
| Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy Abatacept, Dexamethasone, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2018-09-11 | 2025-03-04 |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine - Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2018-08-17 | 2026-08-11 |
| Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 2 | Terminated | Mayo Clinic | 21 | 2018-08-14 | 2026-05-05 |
| Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 13 | 2018-06-19 | 2024-01-09 |
| Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 8 | 2017-07-24 | 2023-09-21 |
| Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma Daratumumab, Dexamethasone, Ixazomib Citrate - Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 80 | 2017-04-20 | 2025-06-04 |
| Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Dexamethasone, Ixazomib, Lenalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Completed | Emory University | 70 | 2016-09-01 | 2025-06-26 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Ixazomib Citrate, Laboratory Biomarker Analysis, Rituximab - Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 2 | Active not recruiting | University of Washington | 33 | 2016-05-19 | 2026-07-01 |
| Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Ixazomib, Rituximab - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Emory University | 12 | 2016-03-01 | 2023-05-09 |
| Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide - Plasma Cell Myeloma, Transplant-Related Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 30 | 2015-12-30 | 2026-09-25 |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Idasanutlin, Ixazomib Citrate - Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 33 | 2015-12-30 | 2024-09-19 |
| Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis - Plasma Cell Leukemia, Plasma Cell Myeloma | Phase 2 | Completed | Mayo Clinic | 17 | 2015-12-24 | 2023-10-30 |
| Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease Ixazomib Citrate, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Chronic Graft Versus Host Disease | Phase 2 | Completed | Fred Hutchinson Cancer Center | 50 | 2015-12-08 | 2019-02-06 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma Clarithromycin, Dexamethasone, Ixazomib Citrate - Myeloma | Phase 1 / Phase 2 | Completed | Joseph Tuscano | 32 | 2015-10-22 | 2026-11-02 |
| Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Gemcitabine Hydrochloride, Ixazomib Citrate - Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 57 | 2015-07-03 | 2025-11-10 |
Showing 20 of 25. Sign in to see all of them.
Multiple Myeloma (15) · Lymphoma, Mantle-Cell (3) · Waldenstrom Macroglobulinemia (2) · Amyloidosis (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Chromosome 17 deletion (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Plasma Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Mayo Clinic (8) · M.D. Anderson Cancer Center (4) · Emory University (2) · Fred Hutchinson Cancer Center (2) · AIDS Malignancy Consortium (1) · City of Hope Medical Center (1) · Joseph Tuscano (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · Roswell Park Cancer Institute (1) · Takeda (1) · University of Chicago (1) · University of Washington (1)
United States (23) · Brazil (1)
Shaji Kumar, M.D. (3) · Ajay K. Gopal (1) · Amrita Krishnan (1) · Andrzej Jakubowiak (1) · Arlene O Siefker-Radtke (1) · Asher A. Chanan-Khan, M.D. (1) · Barbara Pro, MD (1) · Erin Reid, MD (1) · Hun J Lee (1) · Jens Hillengass, MD, PhD (1) · Jonathon Cohen, MD, MS (1) · Joseph Tuscano (1) · Krina Patel (1) · Leon Bernal-Mizrachi, MD (1) · Leona Holmberg (1)
PMID 27702799, PMID 35737873, PMID 36180329, PMID 36385536, PMID 38237077, PMID 40948663
P30CA138292 (2), P30CA014599 (1), P30CA015083 (1), P30CA015704 (1), P30CA060553 (1), UM1CA121947 (1), UM1CA186644 (1)